Implementation of Empagliflozin in Patients with Diabetes Mellitus Type  2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden

ConclusionEmpagliflozin treatment would reduce mortality and healthcare utilization in the patient group. The treatment strategy should be considered cost-effective, supporting a broad implementation of empagliflozin for patients with T2D and established CVD, in line with current national and international guidelines.

Source: Diabetes Therapy - October 5, 2020 Category: Endocrinology Source Type: research